

# CITATION REPORT

List of articles citing

**Bisphosphonate-induced osteonecrosis of the jaws:  
prospective study of 80 patients with multiple  
myeloma and other malignancies**

**DOI: 10.1016/j.oraloncology.2007.11.012**  
**Oral Oncology, 2008, 44, 857-69.**

**Source:** <https://exaly.com/paper-pdf/43818823/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
208	Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. <b>2008</b> , 54, 1066-72		123
207	Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications. <b>2008</b> , 106, e18-21		9
206	Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. <b>2008</b> , 139, 1674-7		118
205	Bisphosphonate-associated osteomyelitis of the jaw: guidelines for practicing clinicians. <b>2008</b> , 14, 1150-68		8
204	Management of osteoporosis in the aging male: focus on zoledronic acid. <b>2009</b> , 4, 289-303		12
203	Mechanism, prevention, risk assessment and treatment in bisphosphonates induced osteonecrosis of the jaw. <b>2009</b> , 39, 1		2
202	Bisphosphonates and time to osteonecrosis development. <b>2009</b> , 14, 1154-66		66
201	Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. <i>Oral Oncology</i> , <b>2009</b> , 45, 551-4	4.4	55
200	The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. <b>2009</b> , 67, 85-95		220
199	Reply to Athanassios Kyrgidis, Zisis Teleioudis and Konstantinos Vahtsevanos [Letter to the Editor re: Christian Walter, Bilal Al-Nawas, Knut A. Grätz, et al. Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. <i>Eur Urol</i> 2008;54:1066-72. <b>2009</b> , 55, e74-e75]		
198	Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. <b>2009</b> , 115, 1631-7		58
197	Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. <b>2009</b> , 15, 527-37		36
196	Osteonecrosis of the mandible associated with bisphosphonate therapy: report of a case with surgical intervention. <b>2009</b> , 2, 153-157		
195	Effects of bisphosphonates on keratinocytes and fibroblasts having a role in the development of osteonecrosis of the jaw. <b>2009</b> , 2, 153-159		22
194	A survey of consultant members of the British Association of Oral and Maxillofacial Surgeons regarding bisphosphonate-induced osteonecrosis of the jaws. <b>2009</b> , 47, 598-601		9
193	Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?. <b>2009</b> , 108, e1-8		23
192	Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. <b>2009</b> , 37, 291-7		50

191	P1.45. Bisphosphonate-related osteonecrosis of the jaw: Clinical series (45 patients). <b>2009</b> , 3, 137-138	
190	Preserving functional independence in elderly patients with cancer-associated bone disease: the role of zoledronic acid. <b>2009</b> , 5, 151-164	2
189	Miscellaneous drugs, materials, medical devices, and techniques. <b>2010</b> , 32, 891-902	1
188	Adverse effects of bisphosphonates. <b>2010</b> , 86, 421-35	108
187	Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. <b>2010</b> , 28, 365-83	206
186	Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. <b>2010</b> , 14, 35-41	113
185	Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. <b>2010</b> , 136, 363-70	18
184	Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. <b>2010</b> , 18, 449-60	116
183	A systematic review of bisphosphonate osteonecrosis (BON) in cancer. <b>2010</b> , 18, 1099-106	72
182	The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. <b>2010</b> , 8, 40-8	73
181	Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case. <b>2010</b> , 68, 863-7	11
180	Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. <b>2010</b> , 68, 2241-7	74
179	Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. <b>2010</b> , 68, 2837-45	110
178	Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. <b>2010</b> , 6, 11	60
177	A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. <b>2010</b> , 3, 6	25
176	An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. <b>2010</b> , 39, 697-702	41
175	Relationship between periodontal disease and osteoporosis. <b>2010</b> , 8, 129-39	24
174	Clinical feature and treatment of bisphosphonate-related osteonecrosis of jaw about oral bisphosphonate administrated patients: case reports. <b>2010</b> , 36, 508	

173	Pain management in multiple myeloma. <b>2010</b> , 10, 415-25	14
172	Jaw bone changes in rats after treatment with zoledronate and pamidronate. <b>2010</b> , 109, 385-91	53
171	Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. <b>2010</b> , 110, 46-53	54
170	Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. <b>2010</b> , 123, 1060-4	180
169	Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. <b>2010</b> , 28, 179-84	72
168	Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. <b>2011</b> , 7, 34-42	83
167	Adverse effects of bisphosphonates. <b>2011</b> , 7, 189-197	
166	Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. <b>2011</b> , 39, 65-8	42
165	Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence—a multi-centre study. <b>2011</b> , 39, 272-7	92
164	[Adverse effects of bisphosphonates]. <b>2011</b> , 7, 189-97	10
163	[Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma]. <b>2011</b> , 32, 494-505	5
162	Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. <b>2011</b> , 112, 195-202	57
161	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. <b>2011</b> , 11, 593-603	26
160	BISPHOSPHONATE-INDUCED MAXILLOFACIAL OSTEONECROSIS IN OSTEOPOROTIC INDIVIDUALS. <b>2011</b> , 46, 495-9	2
159	Guidelines for supportive care in multiple myeloma 2011. <b>2011</b> , 154, 76-103	138
158	Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. <b>2011</b> , 13, 58-63	27
157	Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. <b>2011</b> , 69, 84-91	106
156	Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. <b>2011</b> , 69, 2488-93	36

155	Bisphosphonate related osteonecrosis of the jaw--manifestation in a microvascular iliac bone flap. <i>Oral Oncology</i> , <b>2011</b> , 47, 425-9	4.4	28
154	Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. <b>2011</b> , 137, 907-13		92
153	Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study. <b>2011</b> , 268, 1219-1225		25
152	Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. <b>2011</b> , 15, 105-11		87
151	Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. <b>2011</b> , 15, 127-39		57
150	Low-level laser therapy supported teeth extractions of two patients receiving IV zoledronate. <b>2011</b> , 26, 569-75		16
149	Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?. <b>2011</b> , 26, 815-23		60
148	Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 1871-82	6.3	154
147	Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. <b>2011</b> , 16, 121-32		99
146	Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. <b>2011</b> , 38, 1396-402		51
145	Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. <b>2011</b> , 90, 439-44		147
144	Osteonecrosis of the jaw and the role of macrophages. <b>2011</b> , 103, 232-40		107
143	Zoledronic acid: multiplicity of use across the cancer continuum. <b>2011</b> , 11, 999-1012		11
142	Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. <b>2011</b> , 142, 1243-51		242
141	Pain in malignant hematology. <b>2011</b> , 4, 81-93		13
140	Forced eruption as an alternative to tooth extraction in long-term use of oral bisphosphonates: review, risks and technique. <b>2012</b> , 143, 1303-12		12
139	Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. <b>2012</b> , 40, 303-9		151
138	Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. <b>2012</b> , 40, 719-25		86

137	Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. <b>2012</b> , 51, 882-7		29
136	Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: a case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw. <b>2012</b> , 113, 41-7		8
135	Radiographic evaluation of maxillofacial region in oncology patients treated with bisphosphonates. <b>2012</b> , 114, S19-25		26
134	Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. <i>Oral Oncology</i> , <b>2012</b> , 48, 753-7	4.4	38
133	Bisphosphonate-related osteonecrosis of the jaws--a review. <i>Oral Oncology</i> , <b>2012</b> , 48, 938-947	4.4	97
132	Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. <b>2012</b> , 16, 1143-52		44
131	Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. <i>Oral Oncology</i> , <b>2012</b> , 48, 79-84	4.4	82
130	The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. <i>Oral Oncology</i> , <b>2012</b> , 48, 349-54	4.4	54
129	Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. <b>2013</b> , 5, 1		62
128	Bisphosphonatassoziierte Kiefernekrose. <b>2013</b> , 6, 101-106		0
127	Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. <b>2013</b> , 41, 694-8		63
126	Dynamic analysis of technetium-99m HMDP accumulation and its effect on regional bone metabolism and bone blood flow in bisphosphonate-related osteonecrosis of the jaw. <b>2013</b> , 29, 135-139		5
125	Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin?. <b>2013</b> , 116, 287-92		34
124	Bisphosphonate-associated osteonecrosis of the jaws in lung cancer patients. <b>2013</b> , 19, 228-232		1
123	Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins. <b>2013</b> , 42, 405-8		16
122	[Bisphosphonate-associated osteonecrosis of the jaws in lung cancer patients]. <b>2013</b> , 19, 228-32		1
121	Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw. <b>2013</b> , 10, 1-8		30
120	The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months. <b>2014</b> , 18, 1299-1304		17

119	Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. <b>2013</b> , 60, 741-7	31
118	Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases. <b>2013</b> , 6, 147-54	21
117	Intravenous bisphosphonate-related osteonecrosis of the jaws: influence of coadjuvant antineoplastic treatment and study of buccodental condition. <b>2013</b> , 18, e194-200	5
116	Risk factors and indices of osteomyelitis of the jaw in osteoporosis patients: results from a hospital-based cohort study in Japan. <b>2013</b> , 8, e79376	5
115	New dimensional staging of bisphosphonate-related osteonecrosis of the jaw allowing a guided surgical treatment protocol: long-term follow-up of 266 lesions in neoplastic and osteoporotic patients from the university of bari. <b>2014</b> , 2014, 935657	21
114	The "CROMa" Project: A Care Pathway for Clinical Management of Patients with Bisphosphonate Exposure. <b>2014</b> , 2014, 719478	3
113	Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. <b>2014</b> , 2014, 298945	32
112	Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study. <b>2014</b> , 10, 117-23	18
111	Bisphosphonate-related osteonecrosis of the jaw: specificities. <b>2014</b> , 8, 254	30
110	Bisphosphonate-related osteonecrosis of the jaws: analysis of a case series at a dental school. <b>2014</b> , 34, 77-83	11
109	Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. <b>2014</b> , 117, e429-35	45
108	American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <b>2014</b> , 72, 1938-56	1448
107	Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?. <b>2014</b> , 72, 903-10	30
106	Cone beam computed tomography for diagnosis of bisphosphonate-related osteonecrosis of the jaw: evaluation of quantitative and qualitative image parameters. <b>2014</b> , 43, 1669-78	24
105	A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). <i>Oral Oncology</i> , <b>2014</b> , 50, 1049-57	4.4 115
104	Atraumatic tooth extraction in patients taking bisphosphonates: a review of literature and experience with three cases. <b>2014</b> , 18, 341-9	6
103	Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?. <b>2014</b> , 19, 312-9	32
102	Anti-resorptive osteonecrosis of the jaws: facts forgotten, questions answered, lessons learned. <b>2014</b> , 26, 171-91	12

101	Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. <b>2014</b> , 85, 226-33	51
100	Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). <b>2014</b> , 42, e157-64	36
99	Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. <b>2014</b> , 18, 391-9	19
98	Surgical neurolysis for the treatment of neuropathic pain in 2 postmenopausal women with mandibular necrosis resulting from oral bisphosphonates. <b>2014</b> , 25, 1369-71	3
97	Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws. <b>2015</b> , 10, 439-442	12
96	Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. <b>2015</b> , 22, 151-65	46
95	Quantitative ultrasound at the hand phalanges in patients with bisphosphonate-related osteonecrosis of the jaws. <b>2015</b> , 29, S1806-83242015000100301	1
94	Establishment of an Animal Model of Bisphosphonate-Related Osteonecrosis of the Jaws in Spontaneously Diabetic Torii Rats. <b>2015</b> , 10, e0144355	11
93	Nitrogen-containing bisphosphonates modulate the antigenic profile and inhibit the maturation and biomineralization potential of osteoblast-like cells. <b>2015</b> , 19, 895-902	20
92	The effects of zoledronic acid and dexamethasone on osseointegration of endosseous implants: histological and histomorphometrical evaluation in rats. <b>2015</b> , 26, e17-e21	12
91	High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. <b>2015</b> , 43, 396-401	33
90	Drug induced osteonecrosis of the jaw. <b>2015</b> , 41, 455-64	55
89	Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. <b>2015</b> , 44, 568-85	176
88	Pathophysiology of Osteonecrosis of the Jaws. <b>2015</b> , 27, 489-96	69
87	Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma. <b>2015</b> , 53, 1007-11	5
86	Surgical treatment of bisphosphonate-associated osteonecrosis: Prognostic score and long-term results. <b>2015</b> , 43, 1809-22	28
85	Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. <b>2015</b> , 141, 749-58	20
84	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 3-23	6.3 680



83	Risk Factors for Medication-Related Osteonecrosis of the Jaw. <b>2015</b> , 27-42	1
82	Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma. <b>2015</b> , 13, 229-36	13
81	Doxycycline fluorescence-guided Er:YAG laser ablation combined with Nd:YAG/diode laser biostimulation for treating bisphosphonate-related osteonecrosis of the jaw. <b>2015</b> , 119, e6-e12	11
80	Implant Placement Adjacent to Successfully Treated Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). <b>2015</b> , 41 Spec No, 377-81	5
79	Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. <b>2015</b> , 30, 235-52	51
78	Tooth alterations in areas of bisphosphonate-induced osteonecrosis. <b>2015</b> , 19, 489-95	10
77	Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. <b>2016</b> , 4,	15
76	Bisphosphonates. <b>2016</b> , 996-1001	
75	Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease. <b>2016</b> , 90, 133-41	42
74	Utility of 18F-fluorodeoxy glucose and 18F-sodium fluoride positron emission tomography/computed tomography in the diagnosis of medication-related osteonecrosis of the jaw: A preclinical study in a rat model. <b>2016</b> , 44, 357-63	9
73	Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. <b>2016</b> , 44, 1689-1693	29
72	Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla. <b>2016</b> , 12, 3	10
71	Zoledronic acid suppresses transforming growth factor- $\beta$ -induced fibrogenesis by human gingival fibroblasts. <b>2016</b> , 38, 139-47	12
70	The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws. <b>2016</b> , 44, 369-73	21
69	Do measurements of inflammatory mediators in blood predict recurrence in patients with bisphosphonate-related osteonecrosis of the jaws?. <b>2016</b> , 54, 286-9	2
68	Free flap reconstruction for patients with bisphosphonate related osteonecrosis of the jaws after mandibulectomy. <b>2016</b> , 44, 142-7	15
67	Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. <b>2017</b> , 39, 1	22
66	Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ). <b>2017</b> , 45, 357-363	21

65	Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw. <b>2017</b> , 46, 871-876	24
64	MRONJ risk reduction pathway - 360 degree survey. <b>2017</b> , 222, 386-390	4
63	Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts. <b>2017</b> , 45, 1251-1257	2
62	Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. <b>2017</b> , 148, 584-594.e2	40
61	Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. <b>2017</b> , 23, 477-483	60
60	Appendix: Suggested Reading. <b>2017</b> , 699-741	
59	Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics. <b>2017</b> , 22, e582-e585	12
58	Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat. <b>2018</b> , 22, 2997-3006	17
57	Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro. <b>2018</b> , 22, 2527-2534	22
56	Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment. <b>2018</b> , 24, 1029-1036	2
55	Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw. <b>2018</b> , 76, 877-885	21
54	Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. <b>2018</b> , 18, 142-152	7
53	Combined effect of recombinant human bone morphogenetic protein-2 and low level laser irradiation on bisphosphonate-treated osteoblasts. <b>2018</b> , 44, 259-268	4
52	Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw. <b>2018</b> , 44, 174-181	9
51	Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. <i>Oral Oncology</i> , <b>2018</b> , 84, 104-105	4.4 1
50	Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. <b>2019</b> , 37, 2270-2290	112
49	Histatin-1 counteracts the cytotoxic and antimigratory effects of zoledronic acid in endothelial and osteoblast-like cells. <b>2019</b> , 90, 766-774	10
48	Positive impact of Platelet-rich plasma and Platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid. <b>2019</b> , 9, 8310	22

47	The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis. <b>2019</b> , 11, 1758835919855235	4
46	Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. <b>2019</b> , 9, e025600	7
45	Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats. <b>2019</b> , 47, 349-356	11
44	Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review. <b>2020</b> , 49, 183-191	10
43	Teeth extraction revealing mandibular IgA-multiple myeloma recurrence. <i>Oral Oncology</i> , <b>2020</b> , 100, 104456	11
42	Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis. <b>2020</b> , 24, 133-144	10
41	A review on osteoclast diseases and osteoclastogenesis inhibitors recently developed from natural resources. <b>2020</b> , 142, 104482	14
40	Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. <b>2021</b> , 29, 2305-2317	11
39	Medication-related osteonecrosis and osteoradionecrosis of the jaws: Update and current management. <b>2021</b> , 105, 170-187	4
38	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <b>2021</b> , 29, 2509-2517	7
37	The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review. <b>2021</b> , 26, 23	1
36	The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients. <b>2021</b> , 9,	1
35	Bisphosphonate-associated osteonecrosis of the jaw. <b>2021</b> , 70, 49-57	1
34	Oral health condition in cancer patients under bisphosphonate therapy. <b>2021</b> , 29, 7687-7694	1
33	Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. <b>2021</b> ,	0
32	Surgical vs conservative treatment of medication-related osteonecrosis of the jaw: A complex systematic review and meta-analysis. <b>2021</b> , 132, 671-679	0
31	Impact of COVID-19 disease and its treatment on the development of maxillofacial complications. <b>2021</b> , 4, 100169	
30	Epidemiology of Medication-Related Osteonecrosis of the Jaw. <b>2015</b> , 55-61	1

29	Reconstruction of Defect after Treatment of Bisphosphonate-related Osteonecrosis of the Jaw with Staged Iliac Bone Graft. <b>2014</b> , 36, 57-61	2
28	Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. <b>2012</b> , 55, 111-5	25
27	Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review. <b>2012</b> , 16, 210-4	13
26	Usability of surgical treatment in cases of bisphosphonate-related osteonecrosis of the jaw stage 2 with sequestrum. <b>2015</b> , 5, 67-70	2
25	Review and update on drugs related to the development of osteonecrosis of the jaw. <b>2020</b> , 25, e71-e83	33
24	Biphosphonates in the Treatment of Bone Metastases [Osteonecrosis of the Jaw. <b>2009</b> , 251-262	
23	Osteonecrosis of the Jaw. <b>2010</b> , 133-149	
22	Oral presentation of haematological disease. <b>2012</b> , 3, 104-111	
21	Ost�n�roses des maxillaires dues aux bisphosphonates administr�s par voie intraveineuse : incidence et facteurs de risque. <b>2013</b> , 19, 21-31	2
20	Int�r�t de l'oxyg�oth�rapie hyperbare dans la pr�vention et le traitement des ost�n�roses des maxillaires dues aux bisphosphonates. <b>2013</b> , 19, 91-99	
19	Post-Transplantation Bone Disease: Prevalence, Monitoring, Prevention, and Management Guidelines. 151-161	
18	Clinical study on the effectiveness of dental management for cancer patients receiving intravenous bisphosphonates. <b>2014</b> , 60, 186-192	1
17	Local and Microvascular Free Flaps in Patients with Medication-Related Osteonecrosis of the Jaw. <b>2015</b> , 93-101	1
16	Bisphosphonate Related Osteonecrosis of the Jaw. <b>2015</b> , 311-331	
15	Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment. <b>2016</b> , 185-192	
14	Effect of intravenous administration of zoledronic acid on jaw bone density in cases having skeletal metastasis: A prospective clinical study. <b>2019</b> , 19, 203-209	
13	Actualizaci�n de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisi�n de literatura. <b>2020</b> , 77, 197-202	1
12	Osteonecrosis of the Jaw. <b>2022</b> , 857-902	

11	Medication-related osteonecrosis of the jaw: An update. <b>2022</b> ,		0
10	Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice.. <b>2022</b> , 14, 16		1
9	A Retrospective Data Analysis for the Risk Evaluation of the Development of Drug-Associated Jaw Necrosis through Dentoalveolar Interventions.. <b>2022</b> , 19,		0
8	Effects of Soft Tissue Closure on Medication-Related Osteonecrosis of the Jaw in a Rabbit Model with Tooth Extraction: A Pilot Study.. <i>BioMed Research International</i> , <b>2021</b> , 2021, 4166770	3	
7	Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by ECTS.. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	2
6	Investigation of the Effect of Linoleic Acid on Vascularization in Experimentally Induce Zoledronic Acid-Related Osteonecrosis in Rats. <i>Mehmet Akif Ersoy Üniversitesi Veteriner Fakültesi Dergisi</i> ,	0.2	
5	Inhibition of HMGB1/RAGE signaling reduces the incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) in mice. <i>Journal of Bone and Mineral Research</i> ,	6.3	0
4	Knowledge, Attitude, and Practices of Physicians and Dentists on Medication-related Osteonecrosis of Jaw (MRONJ): A Cross-Sectional Survey.		0
3	Efficacy of Adjunctive Photobiomodulation in the Management of Medication-Related Osteonecrosis of the Jaw: A Systematic Review. <b>2022</b> , 40, 777-791		0
2	Infections in cancer patients with medication-related osteonecrosis of the jaws. <b>2022</b> , 13, 150-154		0
1	Multiple-Drugs-Related Osteonecrosis of the Jaw in a Patient Affected by Multiple Myeloma: A Case Report. <b>2023</b> , 11, 104		0